BioWorld

Oct. 23, 2002

View Archived Issues

Avigen Restructures To Stretch Cash Reserves To Five Years

When companies with three years of cash restructure to reduce spending - well, that might suggest they don't like the chances of the financing window opening anytime soon. (BioWorld Today) Read More

CV Therapeutics Reports Positive Phase III Study Of Tecadenoson

Read More

Italian Scientists Report Gene Transfer Using Pig Sperm For Human Organ Replacements

Read More

Incara Divests Liver Program Via Sale To Vesta Therapeutics

Read More

Other News To Note

Read More

Enchira's Financial Troubles Now Include Nasdaq Delisting

Read More